Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.

Kenneth A Lichtenstein

TitleAffiliate - NJH
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-MED
Phone303/315-1540

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Althoff KN, Gebo KA, Moore RD, Boyd CM, Justice AC, Wong C, Lucas GM, Klein MB, Kitahata MM, Crane H, Silverberg MJ, Gill MJ, Mathews WC, Dubrow R, Horberg MA, Rabkin CS, Klein DB, Lo Re V, Sterling TR, Desir FA, Lichtenstein K, Willig J, Rachlis AR, Kirk GD, Anastos K, Palella FJ, Thorne JE, Eron J, Jacobson LP, Napravnik S, Achenbach C, Mayor AM, Patel P, Buchacz K, Jing Y, Gange SJ. Contributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the USA and Canada: a collaboration of cohort studies. Lancet HIV. 2019 Feb; 6(2):e93-e104. PMID: 30683625.
      View in: PubMed
    2. Thompson-Paul AM, Lichtenstein KA, Armon C, Palella FJ, Skarbinski J, Chmiel JS, Hart R, Wei SC, Loustalot F, Brooks JT, Buchacz K. Cardiovascular Disease Risk Prediction in the HIV Outpatient Study. Clin Infect Dis. 2016 Dec 01; 63(11):1508-1516. PMID: 27613562.
      View in: PubMed
    3. Pozniak A, Arribas JR, Gathe J, Gupta SK, Post FA, Bloch M, Avihingsanon A, Crofoot G, Benson P, Lichtenstein K, Ramgopal M, Chetchotisakd P, Custodio JM, Abram ME, Wei X, Cheng A, McCallister S, SenGupta D, Fordyce MW. Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study. J Acquir Immune Defic Syndr. 2016 Apr 15; 71(5):530-7. PMID: 26627107.
      View in: PubMed
    4. Escota GV, Mondy K, Bush T, Conley L, Brooks JT, Önen N, Patel P, Kojic EM, Henry K, Hammer J, Wood KC, Lichtenstein KA, Overton ET. High Prevalence of Low Bone Mineral Density and Substantial Bone Loss over 4 Years Among HIV-Infected Persons in the Era of Modern Antiretroviral Therapy. AIDS Res Hum Retroviruses. 2016 Jan; 32(1):59-67. PMID: 26366785.
      View in: PubMed
    5. Lichtenstein KA, Hart RL, Wood KC, Bozzette S, Buchacz K, Brooks JT. Statin Use Is Associated With Incident Diabetes Mellitus Among Patients in the HIV Outpatient Study. J Acquir Immune Defic Syndr. 2015 Jul 01; 69(3):306-11. PMID: 26181706.
      View in: PubMed
    6. Wilson EM, Singh A, Hullsiek KH, Gibson D, Henry WK, Lichtenstein K, Önen NF, Kojic E, Patel P, Brooks JT, Sereti I, Baker JV. Monocyte-activation phenotypes are associated with biomarkers of inflammation and coagulation in chronic HIV infection. J Infect Dis. 2014 Nov 01; 210(9):1396-406. PMID: 24813472.
      View in: PubMed
    7. Baker JV, Hullsiek KH, Singh A, Wilson E, Henry K, Lichtenstein K, Onen N, Kojic E, Patel P, Brooks JT, Hodis HN, Budoff M, Sereti I. Immunologic predictors of coronary artery calcium progression in a contemporary HIV cohort. AIDS. 2014 Mar 27; 28(6):831-40. PMID: 24370480.
      View in: PubMed
    8. Lichtenstein KA, Armon C, Buchacz K, Chmiel JS, Buckner K, Tedaldi E, Wood K, Holmberg SD, Brooks JT. Provider compliance with guidelines for management of cardiovascular risk in HIV-infected patients. Prev Chronic Dis. 2013; 10:E10. PMID: 23347705.
      View in: PubMed
    9. Buchacz K, Baker RK, Palella FJ, Shaw L, Patel P, Lichtenstein KA, Chmiel JS, Vellozzi C, Debes R, Henry K, Overton ET, Bush TJ, Tedaldi E, Carpenter C, Mayer KH, Brooks JT. Disparities in prevalence of key chronic diseases by gender and race/ethnicity among antiretroviral-treated HIV-infected adults in the US. Antivir Ther. 2013; 18(1):65-75. PMID: 23111762.
      View in: PubMed
    10. Lichtenstein KA, Armon C, Nagabhushanam V, Efaw BJ, Frazer-Abel A, Hiserote ME, Alam R. A pilot study to assess inflammatory biomarker changes when raltegravir is added to a virologically suppressive HAART regimen in HIV-1-infected patients with limited immunological responses. Antivir Ther. 2012; 17(7):1301-9. PMID: 22948290.
      View in: PubMed
    11. Rower JE, Meditz A, Gardner EM, Lichtenstein K, Predhomme J, Bushman LR, Klein B, Zheng JH, Mawhinney S, Anderson PL. Effect of HIV-1 infection and sex on the cellular pharmacology of the antiretroviral drugs zidovudine and lamivudine. Antimicrob Agents Chemother. 2012 Jun; 56(6):3011-9. PMID: 22391541.
      View in: PubMed
    12. Koeppe J, Lichtenstein K, Armon C, Chmiel JS, Buchacz K, Wood K, Brooks JT. Factors associated with initiation of prolonged analgesic use among patients in the HIV Outpatient Study (HOPS). Clin J Pain. 2011 Oct; 27(8):699-706. PMID: 21540742.
      View in: PubMed
    13. Armon C, Lichtenstein K. The associations among coping, nadir CD4+ T-cell count, and non-HIV-related variables with health-related quality of life among an ambulatory HIV-positive patient population. Qual Life Res. 2012 Aug; 21(6):993-1003. PMID: 21938643.
      View in: PubMed
    14. Lichtenstein KA, Armon C, Buchacz K, Chmiel JS, Buckner K, Tedaldi EM, Wood K, Holmberg SD, Brooks JT. Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study. Clin Infect Dis. 2010 Aug 15; 51(4):435-47. PMID: 20597691.
      View in: PubMed
    15. Buchacz K, Baker RK, Palella FJ, Chmiel JS, Lichtenstein KA, Novak RM, Wood KC, Brooks JT. AIDS-defining opportunistic illnesses in US patients, 1994-2007: a cohort study. AIDS. 2010 Jun 19; 24(10):1549-59. PMID: 20502317.
      View in: PubMed
    16. Lichtenstein KA. Antiretroviral treatment interruptions and risk of non-opportunistic diseases. Curr HIV/AIDS Rep. 2009 May; 6(2):77-82. PMID: 19358778.
      View in: PubMed
    17. Lichtenstein KA, Armon C, Buchacz K, Chmiel JS, Moorman AC, Wood KC, Holmberg SD, Brooks JT. Initiation of antiretroviral therapy at CD4 cell counts >/=350 cells/mm3 does not increase incidence or risk of peripheral neuropathy, anemia, or renal insufficiency. J Acquir Immune Defic Syndr. 2008 Jan 01; 47(1):27-35. PMID: 17971714.
      View in: PubMed
    18. Lichtenstein K, Balasubramanyam A, Sekhar R, Freedland E. HIV-associated adipose redistribution syndrome (HARS): definition, epidemiology and clinical impact. AIDS Res Ther. 2007 Jul 16; 4:16. PMID: 17634130.
      View in: PubMed
    19. Lichtenstein K, Balasubramanyam A, Sekhar R, Freedland E. HIV-associated adipose redistribution syndrome (HARS): etiology and pathophysiological mechanisms. AIDS Res Ther. 2007 Jun 27; 4:14. PMID: 17597538.
      View in: PubMed
    20. Anderson PL, Lichtenstein KA, Gerig NE, Kiser JJ, Bushman LR. Atazanavir-containing renal calculi in an HIV-infected patient. AIDS. 2007 May 11; 21(8):1060-2. PMID: 17457108.
      View in: PubMed
    21. Kiser JJ, Lichtenstein KA, Anderson PL, Fletcher CV. Effects of esomeprazole on the pharmacokinetics of atazanavir and fosamprenavir in a patient with human immunodeficiency virus infection. Pharmacotherapy. 2006 Apr; 26(4):511-4. PMID: 16553510.
      View in: PubMed
    22. Johnson M, Grinsztejn B, Rodriguez C, Coco J, DeJesus E, Lazzarin A, Lichtenstein K, Wirtz V, Rightmire A, Odeshoo L, McLaren C. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS. 2006 Mar 21; 20(5):711-8. PMID: 16514301.
      View in: PubMed
    23. Lichtenstein KA. Redefining lipodystrophy syndrome: risks and impact on clinical decision making. J Acquir Immune Defic Syndr. 2005 Aug 01; 39(4):395-400. PMID: 16010159.
      View in: PubMed
    24. Johnson M, Grinsztejn B, Rodriguez C, Coco J, DeJesus E, Lazzarin A, Lichtenstein K, Rightmire A, Sankoh S, Wilber R. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS. 2005 Apr 29; 19(7):685-94. PMID: 15821394.
      View in: PubMed
    25. Johnson M, Grinsztejn B, Rodriguez C, Coco J, DeJesus E, Lazzarin A, Lichtenstein K, Rightmire A, Sankoh S, Wilber R. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS. 2005 Jan 28; 19(2):153-62. PMID: 15668540.
      View in: PubMed
    26. Lichtenstein KA, Armon C, Baron A, Moorman AC, Wood KC, Holmberg SD. Modification of the incidence of drug-associated symmetrical peripheral neuropathy by host and disease factors in the HIV outpatient study cohort. Clin Infect Dis. 2005 Jan 01; 40(1):148-57. PMID: 15614705.
      View in: PubMed
    27. Lichtenstein KA, Armon C, Moorman AC, Wood KC, Holmberg SD. A 7-year longitudinal analysis of IL-2 in patients treated with highly active antiretroviral therapy. AIDS. 2004 Nov 19; 18(17):2346-8. PMID: 15577556.
      View in: PubMed
    28. Holmberg SD, Palella FJ, Lichtenstein KA, Havlir DV. The case for earlier treatment of HIV infection. Clin Infect Dis. 2004 Dec 01; 39(11):1699-704. PMID: 15578373.
      View in: PubMed
    29. Anderson PL, Kakuda TN, Lichtenstein KA. The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities. Clin Infect Dis. 2004 Mar 01; 38(5):743-53. PMID: 14986261.
      View in: PubMed
    30. Kosmiski LA, Kuritzkes DR, Sharp TA, Hamilton JT, Lichtenstein KA, Mosca CL, Grunwald GK, Eckel RH, Hill JO. Total energy expenditure and carbohydrate oxidation are increased in the human immunodeficiency virus lipodystrophy syndrome. Metabolism. 2003 May; 52(5):620-5. PMID: 12759894.
      View in: PubMed
    31. Kosmiski L, Kuritzkes D, Lichtenstein K, Eckel R. Adipocyte-derived hormone levels in HIV lipodystrophy. Antivir Ther. 2003 Feb; 8(1):9-15. PMID: 12713059.
      View in: PubMed
    32. Lichtenstein KA, Delaney KM, Armon C, Ward DJ, Moorman AC, Wood KC, Holmberg SD. Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J Acquir Immune Defic Syndr. 2003 Jan 01; 32(1):48-56. PMID: 12514413.
      View in: PubMed
    Lichtenstein's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (176) concept(s)
    _
    Co-Authors Expand Description
    See all (13) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department

    Copyright © 2019 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)